12:00 AM
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

FG-4592: Phase IIb data

An open-label Phase IIb trial in 96 patients with stage 3/4 CKD who were not on dialysis showed that thrice-weekly oral FG-4592 led to an increase in hemoglobin of >=1 g/dL in 96% of patients. Additionally, 93% of patients achieved a hemoglobin response defined as an increase in hemoglobin of >=1 g/dL and an absolute hemoglobin concentration of >=11 g/dL for arms...

Read the full 290 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >